2024-09-24 - Analysis Report
## Vertex Pharmaceuticals Inc. (VRTX) Stock Analysis

**Company Overview:** Vertex Pharmaceuticals Inc. is a biotechnology company that develops and commercializes therapies for serious diseases.

**Performance vs. S&P 500:**

* **Cumulative Return:** VRTX has generated a cumulative return of 168.2%, outperforming the S&P 500 (VOO) with a cumulative return of 133.1%. This represents a 35.1 point difference.
* **Relative Strength:** VRTX currently sits at a relative strength of 71.28% compared to the S&P 500, indicating that it has outperformed the index over the past period.

**Recent Price Movement:**

* **Closing Price:** $460.0
* **5-Day Moving Average:** $472.01
* **20-Day Moving Average:** $478.14
* **60-Day Moving Average:** $481.63
* **Overall Trend:** The stock is currently trading below its 5, 20, and 60-day moving averages, suggesting a short-term downtrend.

**Technical Indicators:**

* **RSI (Relative Strength Index):** 39.52, which indicates that the stock is currently in oversold territory.
* **PPO (Percentage Price Oscillator):** -0.33, which suggests that the stock's momentum is declining.
* **Delta_Previous_Relative_Divergence:** -9.94, indicating a short-term bearish divergence.
* **Expected_Return:** 23.12%, representing the potential 5-year expected return based on current investment levels.

**Recent Earnings and Outlook:**

| Date | EPS | Revenue |
|---|---|---|
| 2024-08-02 | -13.92 | $2.65B |
| 2024-05-07 | 4.26 | $2.69B |
| 2023-11-07 | 4.01 | $2.48B |
| 2023-08-02 | 3.55 | $2.49B |
| 2024-08-02 | 3.55 | $2.49B |

The most recent earnings report for the period ending 2024-08-02 shows a significant decline in EPS compared to previous quarters. Although revenue remained relatively stable, the unexpected decrease in EPS may be a cause for concern. Further investigation into the reasons behind this decline, as well as analyst expectations, is necessary for a more comprehensive analysis.

**Summary:**

* VRTX has significantly outperformed the S&P 500 in terms of cumulative return, suggesting strong long-term growth potential.
* However, the recent price movement and technical indicators suggest a short-term bearish trend.
* The recent earnings report indicates a potential setback with a significant decline in EPS. This warrants further analysis and consideration before making investment decisions.
* The expected return of 23.12% suggests potential for continued growth in the future.

**Overall:**

While VRTX has shown impressive long-term performance, current market conditions, recent earnings, and technical indicators suggest caution. A thorough analysis of the reasons behind the recent earnings decline, future growth potential, and the company's strategic direction is crucial before making any investment decisions.